The Boston Deals You Missed During the Holidays: Cash for Kala Pharma, Funds for ViewFinity, Silver for SCVNGR, & More

1/4/10

Feeling a bit out of the loop on the New England tech and life sciences news? Don’t fret. We’ve compiled the Boston-area deals you may have missed during the last couple of weeks of 2009. There were enough of them to indicate that tech lawyers and execs were quite busy over the break.

—Waltham, MA-based software firm ViewFinity found $8.6 million in Series B funding, according to an SEC filing. The firm, which makes SaaS software for support and management of desktops, laptops, and other computing devices, says on its website that its investors are Chicago-based JK&B Capital and Giza Venture Capital, of Israel and Singapore. The exact investors in the second-round financing were not listed in the regulatory filing.

EnglishCentral reported in an SEC filing that it scooped up new funding in a $3.5 million equity round. I checked out the demo of the firm’s video-based system for learning English online, and it looked like a potentially effective way to pick up the language. Though the participants in the round were not named in the filing, the Lexington, MA-based startup revealed back in October that its backers include Atlas Venture and Google Ventures.

Eye Gate Pharma, of Waltham, brought in $11 million of a planned $22.7 million financing round, according to a regulatory filing. The company, which said back in March 2008 that it had raised $31 million, is developing a drug delivery device that uses electrical currents to put drugs deep into the eye without needles. Company CEO Stephen From told investors back in October that he was raising money to fund a late-stage clinical trial of the firm’s lead drug, a reformulated corticosteroid, for dry eye syndrome

—The state of Massachusetts revealed two days before Christmas all of the Bay State biotechs that had recently been awarded $25 million in tax breaks as an incentive to create more than 900 jobs in the commonwealth over the next year. Not surprisingly, some … Next Page »

Single Page Currently on Page: 1 2

By posting a comment, you agree to our terms and conditions.